Literature DB >> 19005282

Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients.

Salvador E Cabrera, Miguel Cordero, Alicia Iglesias, María P Valverde, Alfonso Domínguez-Gil, María J García.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19005282     DOI： 10.1097/QAD.0b013e3283189c07

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  9 in total

1.  Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.

Authors:  Awewura Kwara; Karen T Tashima; Julie B Dumond; Pamela Poethke; Jaclyn Kurpewski; Angela D M Kashuba; Michael H Court; David J Greenblatt
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

Authors:  Salvador Cabrera Figueroa; Alicia Iglesias Gómez; Almudena Sánchez Martín; María de la Paz Valverde Merino; Alfonso Domínguez-Gil Hurlé; Miguel Cordero Sánchez
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.

Authors:  Tanuja N Gengiah; Nicholas H G Holford; Julia H Botha; Andrew L Gray; Kogieleum Naidoo; Salim S Abdool Karim
Journal:  Eur J Clin Pharmacol       Date:  2011-11-23       Impact factor: 2.953

4.  Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.

Authors:  Almudena Sánchez; Salvador Cabrera; Dolores Santos; M Paz Valverde; Aurelio Fuertes; Alfonso Domínguez-Gil; María J García
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

5.  CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W C Sagoe; Ernest Kenu; Michael H Court
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

Review 6.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

Review 7.  The pregnane X receptor in tuberculosis therapeutics.

Authors:  Amina I Shehu; Guangming Li; Wen Xie; Xiaochao Ma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-12-05       Impact factor: 4.481

Review 8.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

9.  Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.

Authors:  Salvador E Cabrera; Dolores Santos; María P Valverde; Alfonso Domínguez-Gil; Francisco González; Guillermo Luna; María J García
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.